WVE

Wave Life Sciences Ltd. (WVE) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. Wave Life Sciences Ltd. is a clinical-stage biotechnology company developing RNA medicines using its PRISM platform. The company is currently undergoing a Redomiciliation from Singapore to Delaware, with shareholder and High Court approval obtained in mid-2026, expected to take effect in August 2026. The company has no product revenue and relies on collaborations and capital markets for funding.

Key Financial Metrics

Liquidity: As of June 30, 2026, the company held $490.6 million in cash, cash equivalents, and marketable securities. Management expects these resources to fund operations for at least the next 12 months.

Material Changes vs. Prior Period

• Revenue Surge: YTD revenue increased 127% to $40.5 million, primarily driven by the recognition of $35.9 million in deferred revenue related to the AATD performance obligation under the GSK collaboration, which was fully satisfied upon the termination of the AATD license in Q1 2026.
• Expense Growth: Operating expenses increased by $25.2 million YTD compared to 2025. R&D expenses rose $14.6 million due to increased external costs for the INHBE (obesity), AATD, and DMD programs. G&A expenses increased $10.5 million, driven by compensation and external costs.
• Lease Commitment: In June 2026, the company amended its Lexington, MA manufacturing facility lease, extending the term to January 2038. This resulted in a $30.0 million increase to operating lease right-of-use assets and liabilities.
• Capital Structure: Series A preferred shares were fully converted to ordinary shares in March 2026. No sales were made under the "at-the-market" equity program in the first half of 2026.

Outlook, Risks, and Management Commentary

• Redomiciliation: The company is transitioning its corporate domicile to Delaware. This is accounted for as a reorganization of entities under common control.
• Clinical Progress:
  • Obesity (WVE-007): Phase 1 data showed significant reductions in visceral fat and preservation of muscle mass. Phase 2a dosing is underway.
  • AATD (WVE-006): The company regained full rights to this program after the GSK license termination. Interim data showed robust restoration of wild-type AAT protein. An FDA meeting regarding accelerated approval is scheduled for late summer 2026.
  • DMD (WVE-N531): Extension trial ongoing; data showed statistically significant functional improvements and dystrophin expression.
  • HD (WVE-003): FDA granted Orphan Drug Designation; company is preparing an IND for a registrational Phase 2/3 study.
• Risks: The company has never been profitable and expects to incur significant losses. Future funding may be required, and there is no assurance that additional capital will be available on acceptable terms. Clinical trial results may not support further development, and regulatory approvals are uncertain.

Investor Verification Checklist

• Redomiciliation Timeline: Verify the completion date of the Singapore-to-Delaware redomiciliation and any associated tax or legal implications.
• Revenue Sustainability: Confirm the remaining deferred revenue balance ($22.6 million) and the timeline for future recognition, given the one-time nature of the AATD license termination revenue.
• Cash Burn Rate: Monitor the net cash used in operating activities ($113.1 million YTD) against the current cash balance to validate the 12-month liquidity runway.
• Lease Obligations: Review the impact of the new $65.3 million operating lease commitment on future cash flow requirements.
• Clinical Milestones: Track upcoming data readouts for WVE-007 (H2 2026) and the FDA meeting for WVE-006 (late summer 2026) as key value drivers.